643 related articles for article (PubMed ID: 33249136)
1. An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease.
Kong G; Ellul S; Narayana VK; Kanojia K; Ha HTT; Li S; Renoir T; Cao KL; Hannan AJ
Neurobiol Dis; 2021 Jan; 148():105199. PubMed ID: 33249136
[TBL] [Abstract][Full Text] [Related]
2. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington's disease.
Kong G; Cao KL; Judd LM; Li S; Renoir T; Hannan AJ
Neurobiol Dis; 2020 Feb; 135():104268. PubMed ID: 30194046
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the Gut Fungal Community in a Mouse Model of Huntington's Disease.
Kong G; Lê Cao KA; Hannan AJ
Microbiol Spectr; 2022 Apr; 10(2):e0219221. PubMed ID: 35262396
[TBL] [Abstract][Full Text] [Related]
4. What the Gut Tells the Brain-Is There a Link between Microbiota and Huntington's Disease?
Wronka D; Karlik A; Misiorek JO; Przybyl L
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901907
[TBL] [Abstract][Full Text] [Related]
5. Dietary fibre confers therapeutic effects in a preclinical model of Huntington's disease.
Gubert C; Kong G; Costello C; Adams CD; Masson BA; Qin W; Choo J; Narayana VK; Rogers G; Renoir T; Furness JB; Hannan AJ
Brain Behav Immun; 2024 Feb; 116():404-418. PubMed ID: 38142919
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota dysbiosis and Huntington's disease: Exploring the gut-brain axis and novel microbiota-based interventions.
Sharma G; Biswas SS; Mishra J; Navik U; Kandimalla R; Reddy PH; Bhatti GK; Bhatti JS
Life Sci; 2023 Sep; 328():121882. PubMed ID: 37356750
[TBL] [Abstract][Full Text] [Related]
7. Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease.
Stan TL; Soylu-Kucharz R; Burleigh S; Prykhodko O; Cao L; Franke N; Sjögren M; Haikal C; Hållenius F; Björkqvist M
Sci Rep; 2020 Oct; 10(1):18270. PubMed ID: 33106549
[TBL] [Abstract][Full Text] [Related]
8. Multiplatform metabolomic analysis of the R6/2 mouse model of Huntington's disease.
Hashimoto M; Watanabe K; Miyoshi K; Koyanagi Y; Tadano J; Miyawaki I
FEBS Open Bio; 2021 Oct; 11(10):2807-2818. PubMed ID: 34469070
[TBL] [Abstract][Full Text] [Related]
9. Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis.
Lu K; Abo RP; Schlieper KA; Graffam ME; Levine S; Wishnok JS; Swenberg JA; Tannenbaum SR; Fox JG
Environ Health Perspect; 2014 Mar; 122(3):284-91. PubMed ID: 24413286
[TBL] [Abstract][Full Text] [Related]
10. Metagenomics and Faecal Metabolomics Integrative Analysis towards the Impaired Glucose Regulation and Type 2 Diabetes in Uyghur-Related Omics.
Nuli R; Azhati J; Cai J; Kadeer A; Zhang B; Mohemaiti P
J Diabetes Res; 2019; 2019():2893041. PubMed ID: 31828159
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiome and Serum Metabolome Alterations Associated with Isolated Dystonia.
Ma L; Keng J; Cheng M; Pan H; Feng B; Hu Y; Feng T; Yang F
mSphere; 2021 Aug; 6(4):e0028321. PubMed ID: 34346706
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome.
Nishitsuji K; Xiao J; Nagatomo R; Umemoto H; Morimoto Y; Akatsu H; Inoue K; Tsuneyama K
Sci Rep; 2017 Nov; 7(1):15876. PubMed ID: 29158587
[TBL] [Abstract][Full Text] [Related]
13. The microbiota-gut-brain axis in Huntington's disease.
Love CJ; Masson BA; Gubert C; Hannan AJ
Int Rev Neurobiol; 2022; 167():141-184. PubMed ID: 36427954
[TBL] [Abstract][Full Text] [Related]
14. Intravenous MSC-Treatment Improves Impaired Brain Functions in the R6/2 Mouse Model of Huntington's Disease via Recovered Hepatic Pathological Changes.
Yu-Taeger L; El-Ayoubi A; Qi P; Danielyan L; Nguyen HHP
Cells; 2024 Mar; 13(6):. PubMed ID: 38534313
[TBL] [Abstract][Full Text] [Related]
15. Multi-omics Analysis Reveals Key Gut Microbiota and Metabolites Closely Associated with Huntington's Disease.
Qian SX; Bao YF; Li XY; Dong Y; Zhang XL; Wu ZY
Mol Neurobiol; 2024 Jun; ():. PubMed ID: 38850348
[TBL] [Abstract][Full Text] [Related]
16. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
Sun MF; Shen YQ
Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
[TBL] [Abstract][Full Text] [Related]
17. Variations in gut microbiota and fecal metabolic phenotype associated with depression by 16S rRNA gene sequencing and LC/MS-based metabolomics.
Yu M; Jia H; Zhou C; Yang Y; Zhao Y; Yang M; Zou Z
J Pharm Biomed Anal; 2017 May; 138():231-239. PubMed ID: 28219800
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication.
Fröhlich EE; Farzi A; Mayerhofer R; Reichmann F; Jačan A; Wagner B; Zinser E; Bordag N; Magnes C; Fröhlich E; Kashofer K; Gorkiewicz G; Holzer P
Brain Behav Immun; 2016 Aug; 56():140-55. PubMed ID: 26923630
[TBL] [Abstract][Full Text] [Related]
19. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
[TBL] [Abstract][Full Text] [Related]
20. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
